(Circulation. 2000;101:e86.)
© 2000 American Heart Association, Inc.
Circulation Electronic Pages |
Department of General Medicine
Department of Laboratory Medicine
Second Department of Internal Medicine Gunma University School of Medicine, Maebashi, Japan
| Introduction |
|---|
|
|
|---|
We read with great interest the recent report of Gwechenberger et al1 demonstrating that cardiac myocytes in the viable border zone of myocardial infarction exhibited reperfusion-dependent expression of interleukin (IL)-6 mRNA within 1 hour in a canine model of ischemia and reperfusion. These authors point to the first direct histological demonstration of IL-6 mRNA, and they suggest the enhanced expression of IL-6 may exert primary effects on myocardial function, such as reduced contractility, positive protein balance (hypertrophy), and antiapoptosis. We agree with their hypothesis, but this is not the first demonstration of IL-6 expression in the infarcted heart in vivo.
In our report,2 we demonstrated that IL-6 protein was immunohistochemically expressed in the hypertrophied myocardium of patients who died 1 to 7 days after myocardial infarction. The greatest expression of IL-6 was confirmed in the adjacent myocardium in patients who died 3 to 4 days after the onset (2.7±0.4; P<0.05) compared with those who died within 1 to 2 days (1.0±0.3). The diameter of IL-6positive myocytes was significantly (P<0.05) increased in patients who died within 1 to 2 days (1.6±0.2), 3 to 4 days (1.8±0.3), or 5 to 8 days (2.0±0.2) after the onset of myocardial infarction. Moreover, the IL-6positive myocytes were adjacent to the infarcted area, such as in the border zone, and coexpressed with atrial natriuretic peptide (ANP). Our study demonstrated that ischemic myocytes surrounding infarcted myocardium definitely expressed IL-6 proteins in their cytoplasm in the first 7 days after infarction.
Although a link between IL-6 and ANP is not clear, ANP is induced within ventricular myocytes in response to pressure overload, cardiomyopathy, and cardiac hypertrophy.3 4 ANP is also considered a genetic marker for in vivo cardiac hypertrophy.5
These reports suggest that demonstration of IL-6 protein and mRNA in ischemic myocytes surrounding infarcted myocardium may induce cardiac hypertrophy not only in an animal model but also in patients with acute myocardial infarction. These data expand the findings of Gwechenberger et al1 and emphasize that cardiac myocytes in the border zone of myocardial infarction produce IL-6, the key element in myocardial adaptation.
| References |
|---|
|
|
|---|
Department of Medicine, Section of Cardiovascular Sciences, The DeBakey Heart Center, Baylor College of Medicine, Houston, Tex
Section of Leukocyte Biology, Department of Pediatrics, Texas Childrens Hospital, Baylor College of Medicine, Houston, Tex
| Introduction |
|---|
|
|
|---|
We included the suggestion that IL-6 might also induce cardiac hypertrophy in the viable border zone surrounding a myocardial infarction as a speculation. We emphasize that early induction of IL-6 in cardiac myocytes was observed only in reperfused myocardial infarctions and was not seen in the absence of reperfusion. Although the induction of IL-6 might well occur in the absence of reperfusion under certain circumstances, we were unable to demonstrate it in our model despite the fact that dogs are known to have very significant collateral circulation. Hypertrophy occurring after myocyte loss is probably primarily related to the increased hemodynamic load on the remaining viable myocardium and is not dependent on reperfusion.
A more specific protective mechanism is likely to be related to the antiapoptotic effects of IL-6 and its related cytokines. The rapid induction of these cytokines early on reperfusion allows their presence during a time period when such an action might be beneficial. The antiapoptotic effects of IL-6related cytokines were discussed in our article, and we continue to pursue this possibility.
| References |
|---|
|
|
|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |